Comparison of @entity3925 and XXXX for preventing @entity1211 after lumbar spine surgery.

@entity1 @entity548 @entity33285 @entity49 @entity3925 @entity1031 @entity86 @entity1211
BACKGROUND: The aim of this study was to evaluate the effectiveness and safety of @entity3925 for preventing @entity1211 ( @entity1211 ) after lumbar spine surgery. METHODS: In this randomized, controlled study, 665 @entity1 who underwent lumbar surgery were randomly assigned to receive either @entity3925 or @entity33285 . @entity3925 and @entity33285 were used for preventing @entity49 . The occurrence of postoperative efficacy endpoint events ( @entity49 ) and safety endpoint events ( @entity548 ) was compared for each group. RESULTS: Efficacy endpoint results: in the @entity3925 group, there were 6 thrombotic events (1.7 %), 2 cases with severe @entity1211 (0.6 %), and 3 cases with symptomatic @entity1211 (0.9 %). In the @entity33285 group, there were 10 thrombotic events (3.1 %), 4 cases with severe @entity1211 (1.2 %), and 6 cases with symptomatic @entity1211 (1.9 %). Safety endpoint results: in the @entity3925 group, there were 21 cases with @entity548 events (6.2 %), 2 cases with severe @entity548 (0.6 %), and 19 cases with non-severe @entity548 (5.6 %). In the @entity33285 group, there were 21 @entity548 events (6.2 %), 1 case with severe @entity548 (0.3 %), and 16 cases with non-severe @entity548 (4.9 %). The incidences of @entity1031 , including severe and symptomatic @entity1211 , were not significantly different between the two groups (P > 0.05). Bleeding event rates, including severe and non-severe @entity548 , were also not significantly different. CONCLUSIONS: @entity3925 proved to be equally effective as @entity33285 for anticoagulation therapy, with both drugs exhibiting a similar prevention effect against postoperative @entity1211 after lumbar spine surgery, without increasing the risk of @entity86 .
